Cerdelga Becomes First Oral First-Line Therapy For Gaucher Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s Genzyme unit obtains U.S. approval for eliglustat as an oral, first-line therapy for adults with Type 1 Gaucher disease. The new product will augment its market-leading Cerezyme, and the company says it will price Cerdelga at par so that patient/physician choice will not be based upon price.
You may also be interested in...
Two Psoriasis Therapies Grab CHMP Backing For European Approval
Novartis’s Cosentyx and Celgene’s Otezla are expected to be approved and launched in Europe in early 2015 for the dermatological indication.
Sanofi’s CEO Search Will Proceed Deliberately, Weinberg Tells Investors
During a late-stage pipeline overview at Genzyme’s headquarters, Sanofi’s chairman and acting CEO laid out the criteria for a new top exec and said reports of a focus on French candidates stem from someone’s imagination.
Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv
The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share